AbbVie LogoJohnson & Johnson Logo

Pharmaceuticals, Biotech & Life Sciences Brands

AbbVie vs Johnson & Johnson

Structured technology and market comparison · 2026

Direct Feature Comparison

AbbVie · vs · Johnson & Johnson
Direct Feature Comparison: AbbVie vs Johnson & Johnson
Attribute
AbbVie LogoAbbVie
Johnson & Johnson LogoJohnson & Johnson
Market Cluster / SectorPharmaceuticals, Biotech & Life Sciences BrandsPharmaceuticals, Biotech & Life Sciences Brands
Business Model / RoleAdvertiser / BrandAdvertiser / Brand
Platform FocusBiopharmaceutical company developing and commercialising prescription medicines.Large public healthcare manufacturer and commercial products company.
Company Size>5,000 employees>5,000 employees
HeadquartersUnited StatesUnited States
Year Founded20121887
Dossier & Alternatives

Analyze all overlapping signals and tech stacks for AbbVie and Johnson & Johnson

Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.

Compare in PlatformInstant access · 1-click via Google/LinkedIn

Comparison Analysis

What is the main difference between AbbVie and Johnson & Johnson?

When comparing AbbVie and Johnson & Johnson, both platforms operate within the Advertiser / Brand ecosystem. AbbVie is positioned as Biopharmaceutical company developing and commercialising prescription medicines, whereas Johnson & Johnson focuses on Large public healthcare manufacturer and commercial products company. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.

What are the top alternatives to AbbVie and Johnson & Johnson?

When evaluating AbbVie and Johnson & Johnson, enterprise buyers also consider other platforms in Advertiser / Brand. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.

How do the corporate scale, structure, and headquarters of AbbVie and Johnson & Johnson compare?

AbbVie is headquartered in United States (founded in 2012) with >5,000 employees. Johnson & Johnson is based in United States (founded in 1887) with >5,000 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.

Market Signals

Recent Market Signals & Activity: AbbVie vs Johnson & Johnson

Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.

AbbVie Logo

AbbVie

Recent Signals

  • ·SEC APILeadership & People

    AbbVie Director Jennifer L. Davis Resigns Following Align Technology CEO Appointment

    On October 28, 2026, Jennifer L. Davis, a Class II director of AbbVie Inc., notified the Board of Directors of her intent to resign, effective November 2, 2026. The resignation is directly attributable to her recent appointment as Chief Executive Officer at Align Technology, Inc. The company explicitly confirmed that her departure does not stem from any dispute or disagreement regarding AbbVie's operations, policies, or practices.

    • Class II Director Jennifer L. Davis notified AbbVie of her resignation on October 28, 2026, effective November 2, 2026.
    • The resignation was prompted by her appointment as CEO of Align Technology, Inc.
    • AbbVie reported no disagreements or disputes related to company operations, policies, or practices.
  • ·SEC APIM&A & Corporate Finance

    AbbVie Completes Acquisition of Apogee Therapeutics to Expand Immunology Pipeline

    On September 3, 2026, AbbVie Inc. reported via Form 8-K the completion of its acquisition of Apogee Therapeutics, Inc. The transaction adds key clinical-stage immunology assets to AbbVie's portfolio, specifically zumilokibart (APG777) and APG273, targeting inflammatory and dermatological diseases. The filing notes that the acquisition will impact AbbVie's adjusted diluted earnings per share (EPS) guidance for the third quarter and full year 2026, driven by acquired in-process research and development (IPR&D) and milestone expenses.

    • Completed the acquisition of Apogee Therapeutics, Inc. on September 3, 2026.
    • Acquired pipeline assets include clinical-stage candidates zumilokibart (APG777) and APG273.
    • Transaction affects AbbVie's full-year 2026 and third-quarter 2026 adjusted diluted EPS guidance due to acquired IPR&D expenses.
  • ·SEC APIM&A & Corporate Finance

    AbbVie Updates Q3 and FY 2026 EPS Guidance Following $216M Acquired IPR&D Expense

    AbbVie Inc. announced that its reported GAAP and adjusted non-GAAP results for the third quarter of 2026 will include $216 million of pre-tax acquired in-process research and development (IPR&D) and milestones expense. This charge represents an unfavorable impact of approximately $0.11 per diluted share on both GAAP and adjusted non-GAAP bases. Because AbbVie does not model unannounced collaboration, licensing, or asset acquisition expenses into its forecasts, the company updated its guidance to factor in this Q3 charge. Consequently, AbbVie revised its Q3 2026 adjusted diluted EPS guidance to $3.73–$3.77 and updated its full-year 2026 adjusted diluted EPS guidance range to $13.76–$13.96.

    • Pre-tax acquired IPR&D and milestones expense for Q3 2026 is expected to be $216 million.
    • The pre-tax expense represents an unfavorable EPS impact of $0.11 per diluted share for both GAAP and adjusted non-GAAP metrics.
    • Third-quarter 2026 adjusted diluted EPS guidance was revised to $3.73–$3.77.
Johnson & Johnson Logo

Johnson & Johnson

Recent Signals

  • ·SEC APIfinancials

    Johnson & Johnson Furnishes Q3 2026 Earnings Announcement via Current Report

    Johnson & Johnson reported fiscal Q3 2026 sales to customers of $25.40 billion, up 5.9% year-over-year (6.0% operational growth), driven by double-digit growth in Oncology and steady demand in MedTech, which offset biosimilar erosion from STELARA. However, consolidated net earnings collapsed to $210 million (diluted EPS of $0.09) from $5.15 billion in Q3 2025. This sharp profitability decline was primarily caused by a $5.5 billion pre-tax accrual recorded in Other (income) expense, net for a proposed comprehensive settlement of the talc ovarian cancer litigation, alongside a $1.0 billion in-process R&D charge from the Firefly Bio acquisition and ongoing Orthopaedics separation costs.

    • Worldwide sales reached $25.40 billion in Q3 2026 (+5.9% YoY) and $74.77 billion for the first nine months (+7.4% YoY), supported by gains in DARZALEX ($4.24 billion in Q3) and TREMFYA ($2.40 billion in Q3).
    • Net earnings plummeted to $210 million in Q3 2026 due to a $5.5 billion litigation charge to resolve ovarian talc claims and a $1.0 billion acquired IPR&D charge for Firefly Bio, Inc.
    • Total present value of reserves for talc-related legal matters reached approximately $9.0 billion as of September 27, 2026, while the planned separation of the Orthopaedics business remains on track for mid-2027.
  • ·Johnson & JohnsonProduct & Platform Launch

    Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy

    Revolutionary IL-23R targeted oral peptide delivers sustained skin clearance and a favorable safety profile in patients with psoriasis affecting sensitive, highly visible areas of the body. 60% of patients with scalp psoriasis and 89% with genital psoriasis achieved site-specific complete skin clearance at Week 112.

  • ·Johnson & JohnsonProduct & Platform Launch

    A behind-the-scenes look at how Johnson & Johnson manufactures and delivers CAR-T cell therapy for multiple myeloma

    Johnson & Johnson published a behind-the-scenes feature on September 25, 2026, highlighting how the company manufactures and delivers CAR-T cell therapy for multiple myeloma. The article focuses on the complexity of producing and distributing this personalized cancer treatment. No specific clinical data, product names, or commercial terms are disclosed in the provided text.

    • Johnson & Johnson published a behind-the-scenes feature on September 25, 2026.
    • The article focuses on Johnson & Johnson's CAR-T cell therapy manufacturing and delivery for multiple myeloma.
    • The provided article text does not reveal specific product names, trial results, or financial terms.

Start with a company or market. Track what changes.

Create your Polaris7 workspace to explore extended company profiles, organize relevant players into Watchlists, and receive focused briefings when material changes occur.